Accueil Le laboratoire Maladie d'Alzheimer Autres maladies

Associations de familles

 Nouveau

La Recherche

Base de données

Publications VCDN

 2001

 


 Buee L, Delacourte A, Wilhelmsen KC, Miller B, Geschwind D. Related Articles
Neuronal subpopulations and genetic background in tauopathies: a catch 22 story'
Neurobiol Aging. 2001 Jan-Feb;22(1):115-21. No abstract available.
PMID: 11164283 [PubMed - indexed for MEDLINE]

Buée L, Delacourte A. Tau phosphorylation. Chapter 21, In : Functional Neurobiology of Aging, Hof PR & Mobbs C Eds, Academic Press, San Diego CA. pp. 303-320.

  • Delacourte A. Neurofibrillary degeneration: patterns of tau isoform expression in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (K. Iqbal, S.S. Sisodia and Bengt Winblad, editors), John Wiley & Sons, Ltd., Chichester, UK, March-May, 2001


    		Delacourte A. Related Articles
    The molecular parameters of tau pathology. Tau as a killer and a witness.
    Adv Exp Med Biol. 2001;487:5-19. Review. No abstract available.
    PMID: 11403165 [PubMed - indexed for MEDLINE]

    Delacourte A, Sergeant N, Champain D, Wattez A, Maurage C-A, Lebert F, Pasquier F, David J-P. The biochemical spreading of tau and amyloid Beta precursor protein pathologies in aging and sporadic Alzheimer’s disease. Brain Aging, 2001, 1, 33-42
  • 1: Galvan M, David JP, Delacourte A, Luna J, Mena R. Related Articles, Help Links
    Sequence of neurofibrillary changes in aging and Alzheimer's disease: A confocal study with phospho-tau antibody, AD2.
    J Alzheimers Dis. 2001 Aug;3(4):417-425.
    PMID: 12214046 [PubMed - as supplied by publisher]
     
    • 6: Guise S, Braguer D, Carles G, Delacourte A, Briand C. Related Articles
    Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells.
    J Neurosci Res. 2001 Feb 1;63(3):257-67.
    PMID: 11170175 [PubMed - indexed for MEDLINE]

    Les angiopathies amyloïdes cérébrales
    Les angiopathies amyloïdes cérébrales se caractérisent par la présence de dépôts
    protéiques dans la paroi des vaisseaux cérébraux. Leur présentation est variable,
    des formes asymptomatiques aux atteintes sévères de la paroi vasculaire. Elles sont
    souvent méconnues en l’absence d’examen anatomopathologique.
    Didier Leys*, Catherine Masson**, Luc Buee***


    		 Riederer BM, Mourton-Gilles C, Frey P, Delacourte A, Probst A. Related Articles
    Differential phosphorylation of tau proteins during kitten brain development and Alzheimer's disease.
    J Neurocytol. 2001 Feb;30(2):145-58.
    PMID: 11577253 [PubMed - in process]
     

    		 Sergeant N, Sablonniere B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, Vermersch P, Delacourte A. Related Articles
    Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.
    Hum Mol Genet. 2001 Sep 15;10(19):2143-55.
    PMID: 11590131
    reprint of the HMG paper


    McKhann et al (et les 30 participants à la conférence consensus, y compris A. Delacourte).     Clinical and Pathological Diagnosis of Frontotemporal Dementia: Report of Work Group on Frontotemporal Dementia and Pick's Disease . Archives of  Neurology. 2001, 58:1803-1809

    Maurage CA, Sergeant N, Ruchoux MM, Hauw JJ,  Delacourte A. Paradoxical phosphorylation of the serine 199 on tau from young individuals. Neuroreport. Vol 12, N°15, October 2001

     

    ·  Royall DR, Palmer R, Mulroy AR, Polk MJ,  Ed MM, Román GC, David JP, Delacourte A. Pathological Determinants of the Transition to Clinical Dementia in Alzheimer’s disease. Exp. Aging Res, 28, in press

    Leys et al